What the FDA labels say about taking them together
Cyclophosphamide and golimumab
Golimumab's FDA label of September 9, 2025 names cyclophosphamide in its warnings and precautions section; the cyclophosphamide labels PlainMeds reads (4) do not name golimumab. The golimumab label: “In controlled trials of other TNF-blockers in patients at higher risk for malignancies a greater portion of malignancies occurred in the TNF-blocker group compared to the controlled group.”
Check it at the source: the cyclophosphamide FDA label on DailyMed (effective January 19, 2026, Amneal Pharmaceuticals LLC); the golimumab FDA label on DailyMed (effective September 9, 2025, Janssen Biotech, Inc.).
What does the cyclophosphamide label say about golimumab?
Cyclophosphamide's label (effective January 19, 2026) and its 3 other brand-application labels do not name golimumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Cyclophosphamide), Amneal Pharmaceuticals LLC, effective January 19, 2026 (SPL set 520bfe39-dfd5-4a20-9a37-80078afded0d), via openFDA; the full label on DailyMed
What does the golimumab label say about cyclophosphamide?
Golimumab label, warnings and precautionsIn controlled trials of other TNF-blockers in patients at higher risk for malignancies (e.g., patients with chronic obstructive pulmonary disease [COPD], patients with Wegener's granulomatosis treated with concomitant cyclophosphamide) a greater portion of malignancies occurred in the TNF-blocker group compared to the controlled group.
Source: FDA drug label (SIMPONI ARIA), Janssen Biotech, Inc., effective September 9, 2025 (SPL set 9e260a47-55af-4c92-8d88-a86ccc767fff), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cyclophosphamide | Golimumab | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma | Rheumatoid arthritis, Crohn's disease and ulcerative colitis |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $1.67 per capsule 50 mg capsule | $12,890.32 per mL 50 mg/0.5 mL pen injec |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once